Pyruvate dehydrogenase deficiency

Common Name(s)

Pyruvate dehydrogenase deficiency, Pyruvate dehydrogenase complex deficiency

Pyruvate dehydrogenase deficiency is metabolic disorder associated with abnormal function of the mitochondria in cells, thus depriving the body of energy. Progressive neurological symptoms usually start in infancy but may be evident at birth, or in later childhood; these symptoms may include developmental delay, intermittent ataxia, poor muscle tone (hypotonia), abnormal eye movements, or seizures. Severe lethargy, poor feeding, and tachypnea (rapid breathing) commonly occur, especially during times of illness, stress, or high carbohydrate intake. Childhood-onset forms of the condition are often associated with intermittent periods of illness but normal neurological development. Prognosis is difficult to predict due to the many causes of the condition, but in most cases of neonatal and infantile onset, prognosis is described as poor. The most common form of pyruvate dehydrogenase deficiency is caused by mutations in the E1 alpha gene, and is inherited in an X-linked dominant manner; all other forms are caused by various genes and are inherited in an autosomal recessive manner. In addition to directly treating acidosis and providing alternative energy for the body, treatment typically includes dietary supplementation with thiamine, carnitine, and lipoic acids, although not all individuals respond to this therapy.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pyruvate dehydrogenase deficiency" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pyruvate dehydrogenase deficiency" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pyruvate dehydrogenase deficiency" returned 16 free, full-text research articles on human participants. First 3 results:

MRI features of 4 female patients with pyruvate dehydrogenase E1 alpha deficiency.
 

Author(s): Nicholas Ah Mew, Johanna B Loewenstein, Nadja Kadom, Uta Lichter-Konecki, Andrea L Gropman, Jodie M Martin, Adeline Vanderver

Journal: Pediatr. Neurol.. 2011 Jul;45(1):57-9.

 

Pyruvate dehydrogenase complex is a key intramitochondrial multienzyme complex required for the conversion of pyruvate to acetyl-CoA. Most patients with pyruvate dehydrogenase deficiency have a defect in the E1 alpha subunit, associated with mutations in the PDHA1 gene. In this report, ...

Last Updated: 4 Jul 2011

Go To URL
Two patients with clinically distinct manifestation of pyruvate dehydrogenase deficiency due to mutations in PDHA1 gene.
 

Author(s): M Magner, K Vinšová, M Tesařová, Z Hájková, H Hansíková, L Wenchich, P Ješina, V Smolka, T Adam, M Vaněčková, J Zeman, T Honzík

Journal: Prague Med Rep. 2011 ;112(1):18-28.

 

The most common cause of pyruvate dehydrogenase complex (PDHc) deficiency is the deficit of the E1α-subunit. The aim of this study was to describe distinct course of the disease in two boys with mutations in PDHA1 gene and illustrate the possible obstacles in measurement of PDHc ...

Last Updated: 7 Apr 2011

Go To URL
A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate.
 

Author(s): Zongchao Han, Kristen Berendzen, Li Zhong, Ira Surolia, Nitin Chouthai, Weihong Zhao, Njeri Maina, Arun Srivastava, Peter W Stacpoole

Journal: Mol. Genet. Metab.. 2008 Apr;93(4):381-7.

 

We determined the ability of self-complementary adeno-associated virus (scAAV) vectors to deliver and express the pyruvate dehydrogenase E1alpha subunit gene (PDHA1) in primary cultures of skin fibroblasts from 3 patients with defined mutations in PHDA1 and 3 healthy subjects. Cells ...

Last Updated: 18 Mar 2008

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pyruvate dehydrogenase deficiency" returned 3 free, full-text review articles on human participants. First 3 results:

The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.
 

Author(s): Kavi P Patel, Thomas W O'Brien, Sankarasubramon H Subramony, Jonathan Shuster, Peter W Stacpoole

Journal: Mol. Genet. Metab.. 2012 Jan;105(1):34-43.

 

Pyruvate dehydrogenase complex (PDC) deficiency is a genetic mitochondrial disorder commonly associated with lactic acidosis, progressive neurological and neuromuscular degeneration and, usually, death during childhood. There has been no recent comprehensive analysis of the natural ...

Last Updated: 9 Jan 2012

Go To URL
Pyruvate dehydrogenase E1 alpha deficiency: males and females differ yet again.
 

Author(s): H H Dahl

Journal: Am. J. Hum. Genet.. 1995 Mar;56(3):553-7.

 

Last Updated: 13 Apr 1995

Go To URL
Pyruvate dehydrogenase deficiency.
 

Author(s): G K Brown, L J Otero, M LeGris, R M Brown

Journal: J. Med. Genet.. 1994 Nov;31(11):875-9.

 

Last Updated: 16 Mar 1995

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
 

Status: Available

Condition Summary: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency; Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2); Mitochondrial Trifunctional Protein Deficiency; Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency; Glycogen Storage Disorders; Pyruvate Carboxylase Deficiency, Type B; Acyl-coA Dehydrogenase, Type 9

 

Last Updated: 7 Oct 2013

Go to URL